Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astra USA
Patients receive intravenous foscarnet either as induction only for 4 weeks or as induction for 4 weeks followed by maintenance for 22 weeks. All patients are followed for 26 weeks or until relapse.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
AIDS.
CMV GI disease.
You may not be if
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Non-GI CMV disease.
Ulcerative colitis, inflammatory bowel disease, or other condition that may interfere with study results.
Other GI pathogens.
Concurrent Medication:
Excluded:
Drugs that may interact with foscarnet.
Systemic acyclovir, ganciclovir, or acyclovir prodrug.
Drugs known to affect renal function.
Prior Medication:
Excluded:
Prior foscarnet in extremis.
Investigational agents other than 3TC or d4T within 7 days prior to study entry.
Clareo Health | Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease
